The Consortium of Multiple Sclerosis Centers Annual Meeting is the leading research and educational conference for multiple sclerosis healthcare professionals of all disciplines in North America.
Effectiveness and Promise of Glatiramer Acetate Depot in Progressive Multiple Sclerosis: Ehud Marom
June 22nd 2022The president and chief executive officer of Mapi Pharma discussed the positive phase 2 findings of a new formulation of glatiramer acetate to treat progressive forms of MS, as well as the long-term plans for the drug. [WATCH TIME: 5 minutes]
Understanding Treatment Decisions and Differences Between Diroximel Fumarate and Dimethyl Fumarate
June 16th 2022Meghan Garabedian, CRNP, MSN, nurse practitioner at the Penn Neuroscience Center, discussed her presentation at the 2022 CMSC Annual Meeting regarding the patient experience on diroximel fumarate.
Advantages With Extended Release Glatiramer Acetate in Relapsing, Progressive MS: Ehud Marom
June 10th 2022The president and chief executive officer of Mapi Pharma discussed the differences and additional benefits from glatiramer acetate depot, a new intramuscular extended-release version of the known multiple sclerosis medication. [WATCH TIME: 4 minutes]
Expanding the Use of Spinal Cord Atrophy in Multiple Sclerosis: Blake E. Dewey, PhD
June 4th 2022The postdoctoral researcher at the Johns Hopkins Multiple Sclerosis Center shared his perspective on the use of spinal cord atrophy in clinical practice to measure disease progression in MS and how it might become more accessible. [WATCH TIME: 4 minutes]
Patients and Clinicians Perceive Cognitive Deficits Differently in Multiple Sclerosis
June 3rd 2022Clinician-perceived cognitive deficits of patients with multiple sclerosis were significantly predicted by multiple factors, including cognitive scores, depression, and physical disability, but notably not fatigue.
Women With MS Use Social Media to Augment Knowledge and Support: Riley Bove, MD
June 2nd 2022The associate professor of neurology at UCSF Weill Institute for Neurosciences discussed the findings of a social media listening study that suggested women with multiple sclerosis used social media platforms to discuss treatment during and around pregnancy. [WATCH TIME: 4 minutes]
EHR-Incorporated MS Smartform Significantly Cuts Down Patient History Review Time in MS
June 2nd 2022The form, which is freely available through the Epic and Cerner EHR platforms, was developed to streamline and standardize patient data collection to allow clinicians more time with patients and more consistent information.
Using a Holistic Approach to Improving Overall Patient Satisfaction in MS: Louise Palmer, MA
June 2nd 2022The health research assistant at the Shepherd Center discussed the need to improve access to interventions that improve the overall happiness of individuals with multiple sclerosis. [WATCH TIME: 4 minutes]
Shifting Focus From Relapses to Neurodegeneration in MS: Michael Levin, MD, FAAN, FANA
June 2nd 2022The professor of neurology at the University of Saskatchewan discussed the need to improve therapeutics aimed at improving neurodegeneration in patients with multiple sclerosis. [WATCH TIME: 3 minutes]
Women With MS Utilize Social Media to Discuss, Share Safety Concerns on DMT Use During Pregnancy
June 1st 2022Investigators utilized a social media listening tool to evaluate and scale mentions of disease-modifying therapy use by women with multiple sclerosis, with the majority of concerns focused on safety and treatment reinitiation in the postpartum period.
Plasma Neurofilament Level Correlated With Symbol Digit Modality Scores Following Ozanimod Treatment
June 1st 2022Both ozanimod doses were associated with greater median reductions in plasma neurofilament light and mean improvements in SDMT score change than interferon beta-1a at month 12 of treatment.
Tackling Neurodegeneration in MS Through A1 Antibodies: Michael Levin, MD, FAAN, FANA
June 1st 2022The professor of neurology at the University of Saskatchewan discussed his presentation at the 2022 CMSC Annual Meeting on using ribonucleoprotein A1 antibodies to drive neurodegeneration in multiple sclerosis. [WATCH TIME: 4 minutes]
CMSC 2022: What to Expect From the Annual Meeting
May 25th 2022June Halper, MSN, APC-C, MSCN, FAAN, the chief executive officer of the Consortium of Multiple Sclerosis Centers, shared her perspective on what to expect from this year’s annual meeting, which takes place June 1-4, 2022, in National Harbor, Maryland.
Therapeutic Approaches to Fatigue in Multiple Sclerosis: Anna Kratz, PhD
November 17th 2021Discussing cognitive behavioral therapy for patients with MS, the associate professor of Physical Medicine and Rehabilitation and research nonclinical psychologist at the University of Michigan Medicine mentioned different therapeutic options that can benefit this patient population. [WATCH TIME: 3 minutes]